Randomized, placebo-controlled trial of product R, a peptide-nucleic acid immunomodulator, in the treatment of adults infected with HIV

HIV Clinical Trials

Volumn 3, Issue 4, 2002, Pages 272-278

  Levett, Paul N ^a   Hirschman, Shalom Z ^a   Roach, Timothy C ^a   Broome, Hedy ^a   Alexander, Richard J ^a   Fraser, Henry S ^a  

^a Advanced Viral Research Corp   (United States)

Author keywords

HIV; Peptide nucleic acid; Product R

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; IMMUNOMODULATING AGENT; PEPTIDE NUCLEIC ACID; PLACEBO; PRODUCT R; UNCLASSIFIED DRUG; IMMUNOLOGICAL ADJUVANT;

ADULT; ARTICLE; CANDIDIASIS; CARDIOMYOPATHY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HERPES SIMPLEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE COUNT; MALE; OPPORTUNISTIC INFECTION; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; VIRUS LOAD; WEIGHT GAIN; WEIGHT REDUCTION; AIDS RELATED COMPLEX; DOUBLE BLIND PROCEDURE; DRUG EFFECT; IMMUNOLOGY; RANDOMIZATION; VIROLOGY;

ADJUVANTS, IMMUNOLOGIC; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOCYTE COUNT; MALE; PEPTIDE NUCLEIC ACIDS; PLACEBOS; RANDOM ALLOCATION; VIRAL LOAD; WEIGHT GAIN;

EID: 0035986047     PISSN: 15284336     EISSN: None     Source Type: Journal    
DOI: 10.1310/n34a-653t-abf5-8q1r     Document Type: Article

References (25)

1. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter
2. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine
3. Delta: A randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals
4. A trial comparing nucleoside monotherapy with combination therapy in HIV infected adults with CD4 cell counts from 200 to 500 per cubic millimeter
5. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter
6. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naïve patients. A randomized controlled comparison with zidovudine monotherapy
7. Molecular biology and the development of AIDS therapeutics
8. Therapeutic approaches to patients with AIDS
9. Effects of TH1 and TH2 cytokines on CD8+ cell response against human immunodeficiency virus: Implications for long-term survival
10. In vitro effect of interleukin-12 on antigen-specific lymphocyte proliferative responses from persons infected with human immunodeficiency virus type 1
11. Generalized vaccinia successfully treated with lipoprotein-nucleic acid complex (reticulose)
12. Herpes gestationis. A report of two cases
13. A new treatment of herpes zoster, vaccinia and chicken pox
14. Peptide nucleic acids stimulate gamma interferon and inhibit the replication of the human immunodeficiency virus
15. CXCR4 and CCR5 expression by H9 T-cells is downregulated by a peptide-nucleic acid immunomodulator
16. Guidelines for the performance of CD4 T-cell determinations in persons with human immunodeficiency virus infection
17. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection
18. Unbalanced repeated-measures model with structured covariance matrices
19. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus
20. Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/microL
21. Increased plasma human immunodeficiency type 1 burden following antigenic challenge with pneumococcal vaccine
22. T cell activation and human immunodeficiency virus replication after influenza immunization of infected children
23. Immunization with both T cell-dependent and T cell-independent vaccines augments HIV viral load secondarily to stimulation of tumor necrosis factor alpha
24. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients
25. IL-8 and MCP-1 secretion is enhanced by the peptide-nucleic acid immunomodulator, Product R, in U937 cells and primary human monocytes